Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma.
J Bryan IorgulescuPrafulla C GokhaleMaria C SperanzaBenjamin K EschleMichael J PoitrasMargaret K WilkensKara M SorokoChhayheng ChhoeuAine KnottYan GaoMary Jane Lim-FatGregory J BakerDennis M BonalQuang-Dé NguyenGareth R L GrantKeith L LigonPeter K SorgerE Antonio ChioccaAna C AndersonPaul T KirschmeierArlene H SharpeGordon J FreemanDavid A ReardonPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Our preclinical and clinical data indicate that concurrent dexamethasone therapy may be detrimental to immunotherapeutic approaches for patients with GBM.